Skip to main
WGS

WGS Stock Forecast & Price Target

WGS Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GeneDx Holdings is experiencing significant growing pains, causing a recent $65M guidance cut in 2026; however, with its retained data strategy from Sema4 and a potential to monetize its data, the company has promising opportunities for growth, particularly with the rare disease market, which is larger than perceived. As a market-leading rare-disease testing lab services company with a strong track record and 26 years of experience, GeneDx has a significant potential to succeed in the long run.

Bears say

GeneDx Holdings is facing significant challenges, as seen in their recent Q1 miss and lowered guidance for 2026, which was attributed to 5 different factors. Despite the potential of new markets such as pediatricians and newborn screening, conversion of early adopters in these markets may take up to 2 years according to management. Additionally, the company has a history of overpromising and underdelivering, casting doubt on their ability to accurately forecast and provide guidance. As a result, I have a negative outlook on GeneDx Holdings' stock due to these fundamental reasons.

WGS has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GeneDx Holdings Corp (WGS) Forecast

Analysts have given WGS a Strong Buy based on their latest research and market trends.

According to 5 analysts, WGS has a Strong Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GeneDx Holdings Corp (WGS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.